▎ WuXi AppTec content team editor
Meningococcal meningitis (abbreviated as meningeal) is an acute and severe infectious disease caused by Neisseria meningitidis, transmitted through respiratory or throat secretion droplets of patients and carriers, mainly by serogroupS A, B, C, X, W135, or Y.
After Neisseria meningitidis enters the blood circulation, it will form a purulent inflammation, and the incidence is uncertain and difficult to diagnose.
According to the World Health Organization (WHO), if the disease is not diagnosed in time, the mortality rate can reach more than 50%, and may even be life-threatening within 24 hours, and even patients who survive rescue may have severe effects such as mental retardation, hearing impairment and even amputation.
The disease has the highest incidence in children under 5 years of age, especially infants and young children aged 6 months to 2 years.
Image credit: 123RF
According to data from the Public Health Data Center, the epidemic meningoccal meningitis database shows that 1 in 4 children under 1 year of age with cerebral flow has died.
Recently, the State Food and Drug Administration of China (NMPA) announced that the ACYW135 meningococcal polysaccharide conjugate vaccine (CRM197 carrier, trade name: Manhaixin) has been approved.
Screenshot source: NMPA official website
According to public information, this quadrivalent brain conjugate vaccine manhaixin independently developed by a Chinese company has been included in the priority review by the Drug Evaluation Center (CDE) of the State Food and Drug Administration of China, and is intended to be used to prevent epidemic meningococcal meningitis caused by group A, C, Y and W135 meningococcal. It fills the gap in China's innovative vaccine for the prevention and treatment of acute infectious meningitis in young children (under 2 years of age).
ManHaixin covalently combined the four common pathogenic meningococcal serogroups A, C, W135 and Y with the carrier protein CRM197, respectively, making it the first conjugate vaccine in China that covers the largest serum group, making the vaccine more extensively protected.
As Professor Yang Yonghong, former vice president of Beijing Children's Hospital and an expert on children's respiratory and infectious diseases, said: "The development and active application of serogroup coverage of a wider range of brain flow vaccines will be more conducive to the capacity building of brain flow disease prevention and control." ”
It is worth mentioning that in the preparation process of this product, no preservative ingredients such as phenol are added, and no ingredients of animal origin are used, making the vaccine safer, more environmentally friendly, and meeting the needs of special populations.
In addition, the results of manhaixin's clinical trial showed that good safety and immunogenicity were shown after 3 immunization procedures for 3 months of age, 2 immunization procedures for 6-23 months of age, and 1 immunization program for healthy children aged 2-6 years.
It is hoped that the quadrivalent meningococcal conjugate vaccine will come to the patient as soon as possible and provide new options for children to prevent meningitis!